QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces the issuance of 1,311,553 subordinate voting shares (the “Shares”) at a price of $0.352 per Share. The Shares will be issued in settlement of a debt owed to 9294-5039 Québec Inc. (“9294”), a consultant of the Corporation’s wholly-owned subsidiary, Altius Healthcare Inc. (“Altius”), which provided consulting services in connection with importation, distribution and marketing of pharmaceutical products and other healthcare products throughout Canada, as the commercial division of the Corporation, in accordance with an executive consulting agreement dated May 1, 2018. These Shares are issued in settlement of the amount owed to 9294 by Altius, which has been assumed by the Corporation, for an aggregate amount of $461,666.73.